Bio-Rad Laboratories Class A
About: Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Employees: 7,700
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
39% more first-time investments, than exits
New positions opened: 75 | Existing positions closed: 54
32% more call options, than puts
Call options by funds: $5.22M | Put options by funds: $3.94M
3% more funds holding
Funds holding: 427 [Q3] → 441 (+14) [Q4]
1.89% more ownership
Funds ownership: 84.52% [Q3] → 86.41% (+1.89%) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 144 | Existing positions reduced: 144
4% less capital invested
Capital invested by funds: $6.45B [Q3] → $6.2B (-$247M) [Q4]
20% less funds holding in top 10
Funds holding in top 10: 5 [Q3] → 4 (-1) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Wells Fargo Brandon Couillard 14% 1-year accuracy 3 / 21 met price target | 40%upside $345 | Equal-Weight Maintained | 12 Feb 2025 |
RBC Capital Conor McNamara 8% 1-year accuracy 3 / 37 met price target | 95%upside $481 | Outperform Reiterated | 14 Jan 2025 |
Financial journalist opinion
